Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc. (KLDO) priced its initial public offering on Mar 1, 2019 at $15.00 per share, below its $20.00–$22.00 range, raising $75M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $444.5M. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

Kaleido Biosciences, Inc. is a clinical-stage healthcare company developing Microbiome Metabolic Therapies, which are designed to modulate the metabolic output of the microbiome. Its initial candidates are targeted glycans, complex carbohydrates intended to influence microbial metabolism, studied under regulations for research with food.

Status

IPO

Ticker

KLDO

Exchange

Nasdaq Global Select

Priced

Mar 1, 2019

IPO price

$15.00

Price range

$20.00–$22.00

Raised

$75M

Market cap at IPO price

$444.5M

First filed

Jan 11, 2019

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.